A meeting held between President Donald Trump and top pharmaceutical executives showed some tensions over drug pricing policy, tariffs and manufacturing.

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

President Donald Trump has warned a group of major U.S. drugmakers that his administration is set to impose tariffs on ...

Pfizer CEO Albert Bourla supports Trump administration at PhRMA Forum, while CDC postpones vaccine advisory meeting. Atomwise names Steve Worland as CEO, and Biogen licenses Dravet drug.

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

The pharmaceutical industry is framing itself as a key partner for President Trump and HHS Secretary Robert F. Kennedy Jr. in ...

Greek-American Pfizer CEO Dr Albert Bourla faced an unwelcoming reception at the White House during an event celebrating ...

The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Several top lobbying names on Washington, D.C.'s K Street, who have voiced opposition to President Donald Trump in the past, ...

As Republicans gear up to pass the first major tax bill since the 2017 Tax Cuts and Jobs Act, Citibank hired Ernst & Young ...

Overnight comments are most detailed yet in specifying other sectors to be hit and would mark a dramatic widening of trade ...